anti- IL6R antibody

Background

IL6R is a key component of the interleukin-6 (IL6) signaling pathway, consisting of a membrane-bound and soluble form (sIL6R), which binds IL6 and mediates downstream effects via the gp130 co-receptor This interaction activates the JAK/STAT3, MAPK, and PI3K/AKT pathways, regulating immune responses, inflammation, and hematopoiesis IL6R signaling is critical in acute-phase responses, B cell maturation, and T cell proliferation Dysregulation of IL6R activity is implicated in chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus (SLE) In cancer, IL6R signaling supports tumor progression, angiogenesis, and immune evasion Therapeutic targeting of IL6R, such as with tocilizumab, is effective in reducing inflammation and cytokine storm in conditions like COVID-19, autoimmune disorders, and hematological malignancies